BRISTOL-MYERS SQUIBB DOWNSIZING PHARMACEUTICAL GROUP BY 10%
BRISTOL-MYERS SQUIBB DOWNSIZING PHARMACEUTICAL GROUP BY 10%, or approximately 3,000 of the group's 30,000 employees worldwide. Bristol-Myers Squibb announced Jan. 4 that it is restructuring and realigning its businesses, with the focus mainly on the pharmaceutical sales forces and marketing. The 10% reduction in the Pharmaceutical Group is the brunt of a corporate downsizing that is expected to reduce BMS' employee levels by "approximately 5,000" worldwide "during the next two years," the company said. The Pharmaceutical Group will account for 60% of that 5,000-person cutback.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth